Gem Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Gem Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011827
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Gem Pharmaceuticals LLC (Gem Pharmaceuticals) is a clinical-stage biopharmaceutical company that develops proprietary anthracycline derivatives. The company’s pipeline products include GPX-150 for oncology, topical GPX-150 for inflammation, GPX 150 oral formulations and potency analogues programs, and non-cardiotoxic versions of other anthracyclines. It uses proprietary chemical modification platform to generate non-cardiotoxic and generally less toxic versions of all anthracyclines. Gem Pharmaceuticals develops drugs for treatment of diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, transplant and other T-cell mediated disorders. The company’s products are used to eliminate cardiotoxicity side effect in chemotherapeutics. Gem Pharmaceuticals is headquartered in Birmingham, Alabama, the US.

Gem Pharmaceuticals LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Gem Pharma To Raise US$4.5 Million In Venture Financing 10
Partnerships 11
OncBioMune Pharma to Enter into Agreement with Gem Pharma 11
Asset Transactions 12
Monopar Therapeutics Acquires GPX-150 from Gem Pharma 12
Gem Pharmaceuticals LLC – Key Competitors 13
Gem Pharmaceuticals LLC – Key Employees 14
Gem Pharmaceuticals LLC – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gem Pharmaceuticals LLC, Deals By Therapy Area, 2011 to YTD 2017 8
Gem Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gem Pharma To Raise US$4.5 Million In Venture Financing 10
OncBioMune Pharma to Enter into Agreement with Gem Pharma 11
Monopar Therapeutics Acquires GPX-150 from Gem Pharma 12
Gem Pharmaceuticals LLC, Key Competitors 13
Gem Pharmaceuticals LLC, Key Employees 14

★海外企業調査レポート[Gem Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Biovica International AB (BIOVIC B):医療機器:M&Aディール及び事業提携情報
    Summary Biovica International AB (Biovica) is a biotech company that focuses on the development and commercialization of blood-based biomarker assays. The company’s DiviTum is a biomarker test that has been developed to monitor and predict treatment effectiveness in the treatment of solid tumours. D …
  • Arno Therapeutics Inc (ARNI)-製薬・医療分野:企業M&A・提携分析
    Summary Arno Therapeutics Inc (Arno) is a clinical stage biopharmaceutical company that develops products for the treatment of cancer, infectious diseases and other life threatening diseases. The company has exclusive worldwide rights for the development and commercialization of Onapristone (for the …
  • Idemitsu Kosan Co Ltd (5019)-エネルギー分野:企業M&A・提携分析
    Summary Idemitsu Kosan Co., Ltd. (Idemitsu) is an integrated energy company that explores, produces, refines, and sells oil and gas, lubricants, and petroleum products. Apart from petroleum products, the company also manufactures agricultural chemicals, agricultural materials, and other chemicals. I …
  • Werner Enterprises, Inc.:企業の戦略・SWOT・財務分析
    Werner Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Werner Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Hoteli-Metropol AD Ohrid:企業の戦略・SWOT・財務情報
    Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report Summary Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • City Utilities of Springfield:企業の戦略的SWOT分析
    City Utilities of Springfield - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Federal Agricultural Mortgage Corp (AGM):企業の財務・戦略的SWOT分析
    Summary Federal Agricultural Mortgage Corp (Farmer Mac) is a mortgage service provider that offers loan services. The organization’s services include custom solutions, credit protection, USDA guaranteed loan purchase, loan purchase, credit solutions, lending opportunities, and wholesale financing se …
  • FibroStatin SL:製薬・医療:M&Aディール及び事業提携情報
    Summary FibroStatin SL (FibroStatin) is a drug development company that focuses on the development of treatment candidates for drug resistant lung cancer and idiopathic pulmonary fibrosis. The company’s pipeline products include T12/FST12 for NSCLC, GPBP-Mab/FSM26 for idiopathic pulmonary fibrosis a …
  • Freeport-McMoRan Inc:戦略・SWOT・企業財務分析
    Freeport-McMoRan Inc - Strategy, SWOT and Corporate Finance Report Summary Freeport-McMoRan Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Precipio Inc (TBIO):企業の財務・戦略的SWOT分析
    Summary Precipio Inc (Precipio), formerly known as Transgenomic Inc, develops diagnostic tools. The company advances personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. Precipio uses ICE COLD-P …
  • Mundipharma International Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Mundipharma International Ltd (Mundipharma) engages in the research and development of products for the treatment pain management, respiratory, cancer and inflammatory conditions. The company commercializes and launches products within Europe and rest of the world. Mundipharma offers its pro …
  • Sanford Burnham Prebys Medical Discovery Institute-製薬・医療分野:企業M&A・提携分析
    Summary Sanford Burnham Prebys Medical Discovery Institute (Sanford Burnham) is a non-profit public benefit institute that offers medical research services. The institute offers research programs in the field of tumor initiation and maintenance, cancer metabolism and signaling networks, tumor microe …
  • Indianapolis Power & Light Co:発電所・企業SWOT分析
    Indianapolis Power & Light Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • China Eastern Airlines Corporation Limited
    China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Hikma Pharmaceuticals PLC:企業の戦略・SWOT・財務分析
    Hikma Pharmaceuticals PLC - Strategy, SWOT and Corporate Finance Report Summary Hikma Pharmaceuticals PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Olmsted Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Olmsted Medical Center (OMC) is a healthcare service provider that offers patient care and clinical research services. The center offers services in the areas of general surgery, podiatry, pain management, dermatology, plastic surgery, inpatient dietary services, pediatrics, diabetes educati …
  • Antibe Therapeutics Inc (ATE)-製薬・医療分野:企業M&A・提携分析
    Summary Antibe Therapeutics Inc (Antibe) is a biotechnology company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercialize novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen …
  • Marr S.P.A.
    Marr S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Marr S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • EnerVest Ltd:企業のM&A・事業提携・投資動向
    EnerVest Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's EnerVest Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Enerjisa Enerji Uretim AS:電力:M&Aディール及び事業提携情報
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from natural gas, lignite coal, hydro, and wind sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆